IP Library › Granted Patent US 12,674,180
Granted Patent B2
US 12,674,180 · App. 18/056,572 · Granted Jul 7, 2026

CD8-specific antibody constructs and compositions thereof

Inventors: Patricia Ann Cruite (Medford, MA); Shirisha Amatya (Cambridge, MA); Hugh Harding (Framingham, MA); Lauren Pepper MacKenzie (Belmont, MA)
Assignee: Sana Biotechnology, Inc.
C12N15/86A61P35/00A61P35/04C07K14/005C07K14/7051C07K14/70517C07K14/70521C07K14/70578C07K16/2803C07K16/2815A61K38/00A61K2039/505A61K2039/545C07K2317/569C07K2317/622C07K2317/76C07K2317/92C07K2319/02C07K2319/33C12N2740/15043C12N2760/18222C12N2760/18233C12N2760/18271
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,674,180
App. No.
18/056,572
Granted
Jul 7, 2026
Kind
B2
Abstract

Disclosed herein are antibodies or antigen binding fragments thereof that specifically bind human CD8. Also disclosed are fusion proteins comprising a Henipavirus glycoprotein G and CD8 antibodies for targeting and transducing cells expressing CD8. Viral vectors and other compositions containing the fusion proteins, as well as methods of using the fusion proteins, are also disclosed.

Claims (122)

1 . An antibody or antigen binding fragment thereof that binds CD8, comprising a heavy chain variable region (V H ), and a light chain variable region (V L ), wherein the heavy chain variable region comprises three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3), and the light chain variable region comprises three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3), wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, respectively, comprise:

a) SEQ ID NOs: 1, 70, 148, 240, 294, and 333, respectively;

b) SEQ ID NOs: 2, 71, 149, 241, 294, and 334, respectively;

c) SEQ ID NOs: 3, 72, 148, 240, 294, and 333, respectively;

d) SEQ ID NOs: 4, 73, 649, 242, 295, and 335, respectively;

e) SEQ ID NOs: 5, 74, 150, 242, 295, and 336, respectively;

f) SEQ ID NOs: 6, 75, 151, 243, 296, and 337, respectively;

g) SEQ ID NOs: 7, 76, 152, 244, 295, and 338, respectively;

h) SEQ ID NOs: 8, 77, 153, 244, 297, and 339, respectively;

i) SEQ ID NOs: 9, 77, 154, 245, 298, and 340, respectively;

j) SEQ ID NOs: 10, 78, 650, 246, 297, and 341, respectively;

k) SEQ ID NOs: 11, 79, 155, 247, 299, and 342, respectively;

l) SEQ ID NOs: 12, 80, 156, 248, 300, and 343, respectively;

m) SEQ ID NOs: 13, 81, 157, 249, 294, and 344, respectively;

n) SEQ ID NOs: 14, 76, 158, 242, 295, and 345, respectively;

o) SEQ ID NOs: 15, 76, 159, 250, 301, and 346, respectively;

p) SEQ ID NOs: 11, 82, 160, 249, 294, and 347, respectively;

q) SEQ ID NOs: 16, 83, 161, 251, 302, and 340, respectively;

r) SEQ ID NOs: 17, 84, 162, 241, 303, and 348, respectively;

s) SEQ ID NOs: 18, 85, 163, 252, 304, and 349, respectively;

t) SEQ ID NOs: 19, 86, 164, 241, 305, and 350, respectively;

u) SEQ ID NOs: 20, 87, 165, 253, 299, and 351, respectively;

v) SEQ ID NOs: 4, 88, 166, 249, 299, and 352, respectively;

w) SEQ ID NOs: 21, 89, 167, 242, 306, and 353, respectively;

x) SEQ ID NOs: 22, 90, 168, 241, 307, and 354, respectively;

y) SEQ ID NOs: 23, 91, 169, 241, 299, and 355, respectively;

z) SEQ ID NOs: 24, 92, 170, 241, 299, and 356, respectively;

aa) SEQ ID NOs: 25, 93, 171, 254, 308, and 344, respectively;

bb) SEQ ID NOs: 26, 94, 172, 240, 294, and 333, respectively;

cc) SEQ ID NOs: 26, 94, 172, 240, 294, and 333, respectively;

dd) SEQ ID NOs: 1, 79, 174, 255, 294, and 358, respectively;

ee) SEQ ID NOs: 28, 95, 175, 256, 294, and 359, respectively;

ff) SEQ ID NOs: 29, 79, 176, 257, 309, and 360, respectively;

gg) SEQ ID NOs: 1, 96, 177, 240, 294, and 333, respectively;

hh) SEQ ID NOs: 20, 97, 149, 251, 299, and 361, respectively;

ii) SEQ ID NOs: 30, 98, 178, 241, 310, and 362, respectively;

jj) SEQ ID NOs: 31, 99, 179, 240, 311, and 363, respectively;

kk) SEQ ID NOs: 32, 100, 180, 258, 312, and 364, respectively;

ll) SEQ ID NOs: 19, 101, 181, 259, 313, and 333, respectively;

mm) SEQ ID NOs: 33, 102, 182, 242, 314, and 365, respectively;

nn) SEQ ID NOs: 34, 103, 183, 260, 315, and 366, respectively;

oo) SEQ ID NOs: 35, 104, 184, 241, 302, and 367, respectively;

pp) SEQ ID NOs: 36, 105, 185, 261, 316, and 368, respectively;

qq) SEQ ID NOs: 37, 106, 186, 262, 294, and 369, respectively;

rr) SEQ ID NOs: 38, 107, 187, 263, 294, and 344, respectively;

ss) SEQ ID NOs: 39, 108, 188, 264, 317, and 344, respectively;

tt) SEQ ID NOs: 40, 109, 189, 240, 294, and 370, respectively;

uu) SEQ ID NOs: 8, 110, 190, 265, 299, and 371, respectively;

vv) SEQ ID NOs: 41, 111, 191, 266, 299, and 346, respectively;

ww) SEQ ID NOs: 19, 112, 192, 242, 318, and 372, respectively;

XX) SEQ ID NOs: 4, 113, 193, 267, 309, and 373, respectively;

yy) SEQ ID NOs: 4, 114, 194, 268, 302, 344, and 453, respectively;

zz) SEQ ID NOs: 42, 115, 195, 269, 319, 374, and 454, respectively;

aaa) SEQ ID NOs: 43, 77, 196, 270, 320, and 375, respectively;

bbb) SEQ ID NOs: 44, 116, 197, 271, 299, and 376, respectively;

ccc) SEQ ID NOs: 40, 117, 198, 272, 302, and 377, respectively;

ddd) SEQ ID NOs: 40, 118, 199, 259, 302, and 378, respectively;

eee) SEQ ID NOs: 45, 114, 200, 273, 321, and 379, respectively;

fff) SEQ ID NOs: 46, 119, 201, 240, 322, and 380, respectively;

ggg) SEQ ID NOs: 47, 120, 202, 274, 309, and 333, respectively;

hhh) SEQ ID NOs: 48, 121, 203, 252, 302, and 333, respectively;

iii) SEQ ID NOs: 49, 122, 204, 275, 311, and 381, respectively;

jjj) SEQ ID NOs: 44, 123, 205, 276, 311, and 333, respectively;

kkk) SEQ ID NOs: 50, 124, 206, 277, 299, and 382, respectively;

lll) SEQ ID NOs: 51, 77, 207, 278, 294, and 383, respectively;

mmm) SEQ ID NOs: 52, 125, 208, 240, 323, and 384, respectively;

nnn) SEQ ID NOs: 34, 126, 209, 279, 324, and 385, respectively;

ooo) SEQ ID NOs: 53, 127, 210, 280, 294, and 386, respectively;

ppp) SEQ ID NOs: 54, 128, 211, 281, 294, and 387, respectively;

qqq) SEQ ID NOs: 19, 129, 212, 282, 317, and 342, respectively;

rrr) SEQ ID NOs: 19, 130, 213, 242, 295, and 388, respectively;

sss) SEQ ID NOs: 55, 77, 214, 240, 325, and 389, respectively;

ttt) SEQ ID NOs: 8, 77, 215, 241, 326, and 390, respectively;

uuu) SEQ ID NOs: 56, 131, 216, 283, 294, and 344, respectively;

vvv) SEQ ID NOs: 57, 132, 217, 249, 327, and 333, respectively;

www) SEQ ID NOs: 19, 133, 218, 284, 297, and 391, respectively;

XXX) SEQ ID NOs: 58, 79, 219, 240, 294, and 333, respectively;

yyy) SEQ ID NOs: 19, 95, 220, 285, 299, and 342, respectively;

zzz) SEQ ID NOs: 58, 134, 221, 286, 294, and 392, respectively;

aaaa) SEQ ID NOs: 40, 93, 222, 241, 309, and 393, respectively;

bbbb) SEQ ID NOs: 59, 135, 223, 275, 299, and 344, respectively;

cccc) SEQ ID NOs: 19, 136, 224, 287, 302, and 394, respectively;

dddd) SEQ ID NOs: 60, 137, 225, 288, 309, and 333, respectively;

eeee) SEQ ID NOs: 10, 138, 226, 289, 328, and 395, respectively;

ffff) SEQ ID NOs: 19, 139, 227, 241, 329, and 396, respectively;

gggg) SEQ ID NOs: 1, 140, 228, 241, 294, and 397, respectively;

hhhh) SEQ ID NOs: 61, 141, 229, 241, 328, and 395, respectively;

iiii) SEQ ID NOs: 62, 93, 230, 241, 316, and 362, respectively;

jjjj) SEQ ID NOs: 63, 142, 231, 249, 330, 361, and 490, respectively;

kkkk) SEQ ID NOs: 64, 143, 232, 290, 299, and 399, respectively;

IIII) SEQ ID NOs: 65, 79, 233, 241, 331, and 400, respectively;

mmmm) SEQ ID NOs: 66, 79, 234, 241, 299, and 401, respectively;

nnnn) SEQ ID NOs: 19, 144, 235, 241, 332, and 371, respectively;

oooo) SEQ ID NOs: 67, 145, 236, 291, 330, and 402, respectively;

pppp) SEQ ID NOs: 19, 146, 237, 292, 294, and 344, respectively;

qqqq) SEQ ID NOs: 68, 147, 238, 241, 299, and 403, respectively; or

rrrr) SEQ ID NOs: 69, 77, 239, 293, 299, and 404, respectively.

2 . The antibody or antigen binding fragment thereof of claim 1 , comprising a heavy chain variable region (V H ) having an amino acid sequence with at least 90% identity to a sequence selected from SEQ ID NOs: 405-498.

3 . The antibody or antigen binding fragment thereof of claim 1 , comprising a light chain variable region (V L ) having an amino acid sequence with at least 90% identity to a sequence selected from SEQ ID NOs: 499-591.

4 . The antibody or antigen binding fragment thereof of claim 2 , comprising a V H having an amino acid sequence with at least 90% identity to a sequence selected from SEQ ID NOs: 405-498 and a V L having an amino acid sequence with at least 90% identity to a sequence selected from SEQ ID NOs: 499-591.

5 . The antibody or antigen binding fragment thereof of claim 2 , wherein the V H is selected from SEQ ID NOs: 405, 408, 448, and 455, and the V L is selected from 499, 503, 542, and 549.

6 . The antibody or antigen binding fragment thereof of claim 1 , wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, respectively, comprise:

a) SEQ ID NOs: 1, 70, 148, 240, 294, 333, respectively;

b) SEQ ID NOs: 5, 74, 150, 242, 295, 336, respectively;

c) SEQ ID NOs: 40, 109, 189, 240, 294, 370, respectively; or

d) SEQ ID NOs: 43, 77, 196, 270, 320, 375, respectively.

7 . The antibody or antigen binding fragment thereof of claim 1 , which binds to human CD8α or CD8β.

8 . The antibody or antigen binding fragment thereof of claim 1 , which binds to a human CD8α homodimer composed of two α chains.

9 . The antibody or antigen binding fragment thereof of claim 1 , which binds to a human CD8 heterodimer composed of one α chain and one β chain.

10 . The antibody or antigen binding fragment thereof of claim 1 ,

wherein the antigen binding fragment is a Fab, Fab′, F(ab′)2, scFv, (scFv)2, scFv-Fc, or Fv fragment.

11 . The antibody or antigen binding fragment thereof of claim 10 , wherein the antigen binding fragment is a scFv.

12 . The antibody or antigen binding fragment thereof of claim 11 , wherein the V H is on the N-terminal side of the V L .

13 . The antibody or antigen binding fragment thereof of claim 11 , wherein the V L is on the N-terminal side of the V H .

14 . The antibody or antigen binding fragment thereof of claim 11 , wherein the scFv comprises a linker connecting the V H and V L .

15 . The antibody or antigen binding fragment thereof of claim 14 , wherein the linker comprises the amino acid sequence set forth in SEQ ID NOs: 625-627 and 645-648.

16 . The antibody or antigen binding fragment thereof of claim 1 , which binds to human CD8α or human CD8β with a K D of about 400 nM or lower.

17 . The antibody or antigen binding fragment thereof of claim 1 , which binds to M. nemestrina CD8α or M. nemestrina CD8β with a K D of about 5 nM to about 500 nM.

18 . The antibody or antigen binding fragment thereof of claim 1 , which binds to human CD8α or CD8β with a K D of about 5 nM to about 500 nM.

19 . An isolated polynucleotide encoding the antibody or antigen binding fragment thereof of claim 1 .

20 . An isolated vector comprising the polynucleotide of claim 19 .

21 . An isolated host cell comprising the polynucleotide of claim 19 .

Continuity (4)
Continuation 17715253 · Apr 7, 2022
Provisional Application 63299254 · Jan 13, 2022
Provisional Application 63172518 · Apr 8, 2021
Related Publication 20230257773A1 · Aug 17, 2023
References Cited (298)
US 6790641B2 · Schauber et al. · 2004 [cited by applicant]
US 6896881B1 · Russell et al. · 2005 [cited by applicant]
US 7094398B1 · Lieber et al. · 2006 [cited by applicant]
US 9486539B2 · Lee et al. · 2016 [cited by applicant]
US 10040830B2 · Chatterjee et al. · 2018 [cited by applicant]
US 10064958B2 · Lee et al. · 2018 [cited by applicant]
US 11535869B2 · Cruite · 2022 [cited by examiner]
US 11576872B2 · Von Maltzahn et al. · 2023 [cited by applicant]
US 11576982B2 · Lee et al. · 2023 [cited by applicant]
US 11608509B2 · Fejoz et al. · 2023 [cited by applicant]
US 20020150556A1 · Vile et al. · 2002 [cited by applicant]
US 20030072773A1 · Wertz et al. · 2003 [cited by applicant]
US 20030207445A1 · Schauber et al. · 2003 [cited by applicant]
US 20050070493A1 · Fawell et al. · 2005 [cited by applicant]
US 20060045910A1 · Ehringer · 2006 [cited by applicant]
US 20060104950A1 · Okano et al. · 2006 [cited by applicant]
US 20070031455A1 · Audonnet · 2007 [cited by applicant]
US 20070154481A1 · Gelinas · 2007 [cited by examiner]
US 20090041724A1 · Steen et al. · 2009 [cited by applicant]
US 20100316570A1 · Discher et al. · 2010 [cited by applicant]
US 20110184049A1 · Chuah et al. · 2011 [cited by applicant]
US 20120322147A1 · Mangeot et al. · 2012 [cited by applicant]
US 20130273549A1 · Sullivan et al. · 2013 [cited by applicant]
US 20140079774A1 · Brinker · 2014 [cited by applicant]
US 20150050242A1 · Lee et al. · 2015 [cited by applicant]
US 20150133420A1 · Cheng et al. · 2015 [cited by applicant]
US 20150216903A1 · Heffner et al. · 2015 [cited by applicant]
US 20160011197A1 · Walfish et al. · 2016 [cited by applicant]
US 20160354313A1 · Beer et al. · 2016 [cited by applicant]
US 20170087087A1 · Leonard et al. · 2017 [cited by applicant]
US 20170165348A1 · Cantore et al. · 2017 [cited by applicant]
US 20170183686A1 · Khorova et al. · 2017 [cited by applicant]
US 20170189449A1 · Lim · 2017 [cited by applicant]
US 20170296677A1 · Lee et al. · 2017 [cited by applicant]
US 20170368098A1 · Chen et al. · 2017 [cited by applicant]
US 20180028600A1 · Hong et al. · 2018 [cited by applicant]
US 20180028687A1 · Selaru et al. · 2018 [cited by applicant]
US 20180312824A1 · Zhang et al. · 2018 [cited by applicant]
US 20190023790A1 · Regeneron · 2019 [cited by applicant]
US 20190125898A1 · Lee et al. · 2019 [cited by applicant]
US 20190144885A1 · Costa Fejoz et al. · 2019 [cited by applicant]
US 20190271006A1 · Nakaishi et al. · 2019 [cited by applicant]
US 20190351047A1 · Jasny et al. · 2019 [cited by applicant]
US 20200060980A1 · Von Maltzahn et al. · 2020 [cited by applicant]
US 20210030467A1 · Mee et al. · 2021 [cited by applicant]
US 20210032589A1 · Mee et al. · 2021 [cited by applicant]
US 20210137839A1 · Von Maltzahn et al. · 2021 [cited by applicant]
US 20210187018A1 · Von Maltzahn et al. · 2021 [cited by applicant]
US 20210198698A1 · Von Maltzahn et al. · 2021 [cited by applicant]
US 20210228627A1 · Von Maltzahn et al. · 2021 [cited by applicant]
US 20210353543A1 · Trudeau et al. · 2021 [cited by applicant]
US 20210393736A1 · Hong et al. · 2021 [cited by applicant]
US 20220008557A1 · Von Maltzahn et al. · 2022 [cited by applicant]
US 20220241328A1 · Bandoro et al. · 2022 [cited by applicant]
US 20230043255A1 · Von Maltzahn et al. · 2023 [cited by applicant]
US 20230048166A1 · Von Maltzahn et al. · 2023 [cited by applicant]
US 20230068547A1 · Von Maltzahn et al. · 2023 [cited by applicant]
US 20230285591A1 · Lee et al. · 2023 [cited by applicant]
US 20230348934A1 · Fejoz et al. · 2023 [cited by applicant]
US 20240033227A1 · von Maltzahn et al. · 2024 [cited by applicant]
US 20240279685A1 · Lee et al. · 2024 [cited by applicant]
US 20240408192A1 · Bandoro et al. · 2024 [cited by applicant]
US 20250082777A1 · Foster et al. · 2025 [cited by applicant]
US 20250144235A1 · Jain · 2025 [cited by applicant]
US 20250152709A1 · Bandoro et al. · 2025 [cited by applicant]
US 20250333469A1 · Bandoro et al. · 2025 [cited by applicant]
US 20250369018A1 · Von Maltzahn et al. · 2025 [cited by applicant]
EP 1115879 · 2001 [cited by applicant]
EP 2615176 · 2013 [cited by applicant]
EP 3235908 · 2017 [cited by applicant]
EP 3964585 · 2022 [cited by applicant]
JP H10313865 · 1998 [cited by applicant]
JP 2013034401 · 2013 [cited by applicant]
WO WO1995023846 · 1995 [cited by applicant]
WO WO1995032706 · 1995 [cited by applicant]
WO WO1997004748 · 1997 [cited by applicant]
WO WO2000009730 · 2000 [cited by applicant]
WO WO2000017374 · 2000 [cited by applicant]
WO WO2001074861 · 2001 [cited by applicant]
WO WO2001075135 · 2001 [cited by applicant]
WO WO2002002765 · 2002 [cited by applicant]
WO WO2002044206 · 2002 [cited by applicant]
WO WO2006027202 · 2006 [cited by applicant]
WO WO2006028786 · 2006 [cited by applicant]
WO WO2006059141 · 2006 [cited by applicant]
WO WO2006078221 · 2006 [cited by applicant]
WO WO2007005244 · 2007 [cited by applicant]
WO WO2008037458 · 2008 [cited by applicant]
WO WO2008071959 · 2008 [cited by applicant]
WO WO2008081008A1 · 2008 [cited by applicant]
WO WO2008115199 · 2008 [cited by applicant]
WO WO2009130208 · 2009 [cited by applicant]
WO WO2010053489 · 2010 [cited by applicant]
WO WO2010075061 · 2010 [cited by applicant]
WO WO2011011584 · 2011 [cited by applicant]
WO WO2011058052 · 2011 [cited by applicant]
WO WO2012095535 · 2012 [cited by applicant]
WO WO2012149376 · 2012 [cited by applicant]
WO WO2012158643 · 2012 [cited by applicant]
WO WO2012170911 · 2012 [cited by applicant]
WO WO2013045639 · 2013 [cited by applicant]
WO WO2013084000 · 2013 [cited by applicant]
WO WO2013148327 · 2013 [cited by applicant]
WO WO2014076137 · 2014 [cited by applicant]
WO WO2014164553 · 2014 [cited by applicant]
WO WO2015011478 · 2015 [cited by applicant]
WO WO2015110957 · 2015 [cited by applicant]
WO WO2016009326 · 2016 [cited by applicant]
WO WO2016124781 · 2016 [cited by applicant]
WO WO2016138525 · 2016 [cited by applicant]
WO WO2016183482 · 2016 [cited by applicant]
WO WO2016196350 · 2016 [cited by applicant]
WO WO2017005923 · 2017 [cited by applicant]
WO WO2017011519 · 2017 [cited by applicant]
WO WO2017151717 · 2017 [cited by applicant]
WO WO2017165245 · 2017 [cited by applicant]
WO WO2017173034 · 2017 [cited by applicant]
WO WO2017182585 · 2017 [cited by applicant]
WO WO2017211945 · 2017 [cited by applicant]
WO WO2017218850 · 2017 [cited by applicant]
WO WO2018009923 · 2018 [cited by applicant]
WO WO2018022749 · 2018 [cited by applicant]
WO WO2018106732 · 2018 [cited by applicant]
WO WO2018115507 · 2018 [cited by applicant]
WO WO2018129563 · 2018 [cited by applicant]
WO WO2018132479 · 2018 [cited by applicant]
WO WO2018208728 · 2018 [cited by applicant]
WO WO2019086351 · 2019 [cited by applicant]
WO WO2019113512 · 2019 [cited by applicant]
WO WO2019152692 · 2019 [cited by applicant]
WO WO2019157316 · 2019 [cited by applicant]
WO WO2019157319 · 2019 [cited by applicant]
WO WO2019161281 · 2019 [cited by applicant]
WO WO2019217964 · 2019 [cited by applicant]
WO WO2019222403 · 2019 [cited by applicant]
WO WO2020014209 · 2020 [cited by applicant]
WO WO2020092554A1 · 2020 [cited by applicant]
WO WO2020102485 · 2020 [cited by applicant]
WO WO2020102499 · 2020 [cited by applicant]
WO WO2020102503 · 2020 [cited by applicant]
WO WO2020102578 · 2020 [cited by applicant]
WO WO2020121273 · 2020 [cited by applicant]
WO WO2020210003 · 2020 [cited by applicant]
WO WO2021046143 · 2021 [cited by applicant]
WO WO2021168355 · 2021 [cited by applicant]
WO WO2021202604 · 2021 [cited by applicant]
WO WO2021207801 · 2021 [cited by applicant]
WO WO2022010889 · 2022 [cited by applicant]
WO WO2022150731 · 2022 [cited by applicant]
WO WO2022165262 · 2022 [cited by applicant]
WO WO2022216915 · 2022 [cited by applicant]
WO WO2022251712 · 2022 [cited by applicant]
WO WO2023115041 · 2023 [cited by applicant]
WO WO2023133595 · 2023 [cited by applicant]
WO WO2023150518 · 2023 [cited by applicant]
WO WO2023150647 · 2023 [cited by applicant]
WO WO2023193015 · 2023 [cited by applicant]
WO WO2024026377 · 2024 [cited by applicant]
WO WO2024044655 · 2024 [cited by applicant]
WO WO2024064838 · 2024 [cited by applicant]
WO WO2024119157 · 2024 [cited by applicant]
WO WO2024220560 · 2024 [cited by applicant]
WO WO2024243340 · 2024 [cited by applicant]
Holliger and Hudson (Nature Biotechnology Sep. 2005, 23(9): 1126-1136) (Year: 2005). [cited by examiner]
Dianova (Antibody structure—what is a secondary antibody? https://www.dianova.com/en/faq/antibody-structure-what-is-a-secondary-antibody/, downloaded Aug. 14, 2024) (Year: 2024). [cited by examiner]
Abengozar et al., “Blocking ephrinB2 with highly specific antibodies inhibits angiogenesis, lymphangiogenesis, and tumor growth”. Blood 119(19):4565-76, 2012. [cited by applicant]
Aguilar et al. “N-glycans on nipah virus fusion protein protect against neutrilization but reduce membrane fusion and viral entry”, Virol. (80) 4878-4889, 2006. [cited by applicant]
Aguilar et al., “Polybasic KKR Motif in the Cytoplasmic Tail of Nipah Virus Fusion Protein Modulates Membrane Fusion by Inside-Out Signaling,” J Viral (2007) 81:4520-4532. [cited by applicant]
Alam et al., “Coexpression of EphB4 and ephrinB2 in tumor advancement of uterine cervical cancers”, Gynecologic Oncology 114(1):84-88, 2009. [cited by applicant]
Anliker et al., Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors, 7(11) Nature Methods 929-937 (Nov. 2010). [cited by applicant]
Barile et al., “Exosomes: Therapy delivery tools and biomarkers of diseases,” Pharmacol Ther. (2017) 174: 63-78. [cited by applicant]
Bender et al., “Developing an Engineered Nipah Virus Glycoprotein Based Lentiviral Vector System Retargeted to Cell Surface Receptors of Choice,” Mol. Ther. (2015) 23(1); S2. [cited by applicant]
Bender et al., “Receptor-Targeted Nipah Virus Glycoproteins Improve Cell-Type Selective Gene Delivery and Reveal a Preference for Membrane-Proximal Cell Attachment,” PLOS Pathogens 12(6):e1005641. [cited by applicant]
Biering et al. “N-glycans on the nipah virus attachment glycoprotein modulate fusion and viral entry as they protect against antibody neutrilization” J Virol. (2012) 86(22): 11991-12002. [cited by applicant]
Bishop et al., “Identification of Hendra Virus G Glycoprotein Residues That Are Critical for Receptor Binding,” J Viral (2007) 81:5893-5901. [cited by applicant]
Bowden et al., “Structural basis of Nipah and Hendra virus attachment to their cell-surface receptor ephrin-B2,” Nature Structural & Molecular Biology (2008) 15(6):567-572. [cited by applicant]
Chiriaco et al., “Dual-regulated lentiviral vector for gene therapy of X linked chronic granulomatosis.” Molecular Therapy (2014) 22(8): 1472-1483. [cited by applicant]
Enkirch et al., [cited by applicant]
Field et al., “Comparison of lentiviral and sleeping beauty mediated alpha&bgr T cell receptor gene transfer.” PLOS ONE (2013) 8(6): e68201. [cited by applicant]
Frecha et al., [cited by applicant]
Friedel et al., “Receptor-targeted lentiviral vectors are exceptionally sensitive toward the biophysical properties of the displayed single-chain Fv,” Protein Eng Des Sel. (2015) 28(4): 93-106. doi: 10.1093/protein/gzv0… [cited by applicant]
Funke et al., [cited by applicant]
Guillaume et al., “Evidence of a Potential Receptor-Binding Site on the Nipah Virus G Protein (NiV-G): Identification of Globular Head Residues with a Role in Fusion Promotion and Their Localization on an NiV-G Structur… [cited by applicant]
Haga et al.,“Permanent, lowered HLA class I expression using lentivirus vectors with shRNA constructs: averting cytotoxicity by alloreactive T lymphocytes.” Transplantation Proceedings (2006) 38(10):3184-3188. [cited by applicant]
Imamura et al., [cited by applicant]
Khetawat et al., “A Functional Henipavirus Envelope Glycoprotein Pseudotyped Lentivirus Assay System,” Khetawat and Broder Virology Journal (2010) 7:312. [cited by applicant]
Kneissl et al., [cited by applicant]
Lattanzi et al “A Strategy of antigen incoperation into exosomes: Comparing cross-presentation levels of antigens delivered by engineered exosomes and by lentiviral virus-like particles”, Vaccine (2012) col. 20, No. 50;… [cited by applicant]
Leavitt et al., “Concordant modulation of neutrilization resistance and high infectivity of the primary human immunodeficiency virus type 1 MN strain and definition of a potential gp41 binding site in gp120”. Journal of… [cited by applicant]
Lee et al. “Modes of paramyxovirus fusion: a Henipavirus perspective” 2011. Trends in Microbiology.Aug;19(8):389-99. [cited by applicant]
Lentz et al. “Review, viral vectors for gene delivery to the central nervous system” Neurobiology of Disease 48:179-188, 2012. [cited by applicant]
Levy et al., “Surface engineering of lentiviral vectors for gene transfer into gene therapy target cells,” Current Opinion in Pharmacology (2015) 24:79-85. [cited by applicant]
Milani et al., “Genome editing for scalable produciton of alloantigen free lentiviral vectors for in vivo gene therapy.” EMBO Molecular Medicine (2017) 9(11): 1558-1573. [cited by applicant]
Montagna et al., “VSV-G-Enveloped Vesicles for Traceless Delivery of CRISPR-Cas9” Mol Ther Nucleic Acids. (2018) 12:453-462. [cited by applicant]
Morizono et al., “Redirecting lentiviral vectors pseudotyped with sinbis virus-derived envelope proteins to DC-SIGN by modificiation of N-linked glycans of envelope proteins,” J Virol. (2010) 84(14): 6923-34. [cited by applicant]
Munch et al., DARPins: An Efficient Targeting Domain for Lentiviral Vectors, 19(4) Molecular Therapy 686-693 (2011). [cited by applicant]
Munch et al., “Off-target-free gene delivery by affinity-purified receptor-targeted viral vectors,” Nature Communications (2015) 6:6246. [cited by applicant]
Nakamura et al., “Antibody-targeted cell fusion,” Nat Biotechnol. (2004) 22(3): 331-336. [cited by applicant]
Needleman et al., A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins, 48 J. Mol. Biol. 443-453 (1970). [cited by applicant]
Negrete et al., “EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus”, Nature (436)401-405, 2005. [cited by applicant]
Negrete et al., “Single Amino Acid Changes in the Nipah and Hendra Virus Attachment Glycoproteins Distinguish EphrinB2 from EphrinB3 Usage,” J Viral (2007) 81(19):10804-10814. [cited by applicant]
Nordlund et al., “SNARE-fusion mediated insertion of membrane proteins into native and artificial membranes.” Nat Commun. (2014) 5: 4303. [cited by applicant]
Palomares et al., “Nipah Virus Envelope-Pseudotyped Lentiviruses Efficiently Target ephrinB2-Positive Stem Cell Populations In Vitro and Bypass the Liver Sink When Administered In Vivo,” J Viral (2013) 87:2094-2108. [cited by applicant]
Pichard et al., “Specific Micro-RNA regulated TetR-KRAB Transcriptional control of transgene expression in viral vector transduced cells,” PLOS ONE (2012) 7(12):e51952. [cited by applicant]
Riazifar et al., “Stem Cell Extracellular Vesicles: Extended Messages of Regeneration,” Annu Rev Pharmacol Toxicol. (2017) 57: 125-154. [cited by applicant]
Schauber-Plewa et al., “Complement regulatory proteins are incorporated into lentiviral vectors and protect particles against complement inactivation.” Gene Therapy. (2004) 12(3): 238-245. [cited by applicant]
Single Domain Antibodies, Single-Domain Antibodies—MeSH—NCBI (nih.gov), 2013. [cited by applicant]
Sosale et al., “Marker of self: CD47 on lentiviral vectors decreases macrophage-mediated clearance and increases delivery to SIRPA-expressing lung carcinoma tumors.” Molecular Therapy (2016) 3(7): 16080. [cited by applicant]
Stefan et al., “DARPins recognizing the tumor-associated antigen EpCAM selected by phage and ribosome display and engineered for multivalency,” J Mol Biol. (2011) 413(4): 826-43. [cited by applicant]
Steffen et al., “Henipavirus mediated membrane fusion, virus entry and targeted therapeutics,” Viruses (2012) 4:280-309. [cited by applicant]
Tang et al., “Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy.” Oncotarget (2015) 6(42); 44179-44190. [cited by applicant]
Tomas et al., “Improved GaLV-TR glycoproteins to pseudotype lentiviral vectors: impact of viral protease activity in the production of LV pseudotypes.” Molecular Therapy (2019) 15: 1-8. [cited by applicant]
Verhoeyen et al., “Lentiviral vector gene transfer into human T cells,” Methods in Mal Biol (2009) 506:97-114. [cited by applicant]
Verhoeyen et al., [cited by applicant]
Weiss et al., “Review, The blood-brain barrier in brain homeostasis and neurological diseases” Biochimica Biophys Acta. (2009) 1788: 841-857. [cited by applicant]
White et al., “Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme,” Crit Rev Biochem Mol Biol. (2008) 43(3): 189-219. [cited by applicant]
Witting S.R. et al., Characterization of a 3rd Generation Lentiviral Vector Pseudotyped With Nipah Virus Envelope Proteins for Endothelial Cell Transduction. Gene Ther, May 23, 2013, vol. 20, No. 10. [cited by applicant]
Xu et al., “Host cell recognition by the henipaviruses: Crystal structures of the Nipah G attachment glycoprotein and its complex with ephrin-B3,” PNAS (2008) 105(29):9953-9958. [cited by applicant]
Xu et al., “New Insights into the Hendra Virus Attachment and Entry Process from Structures of the Virus G Glycoprotein and Its Complex with Ephrin-B2,” PLOS One (2012) 7(11):e48742. [cited by applicant]
Yang et al., “Virus-mimetic fusogenic exosomes for direct delivery of integral membrane proteins to target cell membranes.” Advanced Materials (2017) 29(13): 1605604. [cited by applicant]
Zakaria et al., “Combination of hepatocyte specific delivery and transformation dependent expression of shRNA inducing transcriptional gene silencing of c-Myc promoter in hepatocellular carcinoma cells”, BMC Cancer, Bio… [cited by applicant]
Zhang et al., “Cell specific targeting of lentiviral vector mediated by fusion proteins derived from Sindbis virus, vesicular stomatitis virus, or avian sarcoma/leukosis virus”, Retrovirology 7(3) 1-15, 2010. [cited by applicant]
Zhou et al., “Cell type specific gene delivery by lentiviral vectors,” Onco Immunolgy (2013) 2:e22566. [cited by applicant]
Zhou Q et al. T cell receptor gene transfer exclusively to human CD8 cells enhances tumor killing. Blood Aug. 16, 2012, vol. 120 No 22:4334. [cited by applicant]
Zhou et al., Exclusive Transduction of Human CD4+ T Cells upon Systemic Delivery of CD4-Targeted Lentiviral Vectors, 195(5) J. Immunol. 2493-2501 (2015). [cited by applicant]
International Search Report issued on Jun. 13, 2017, in corresponding PCT Application No. PCT/EP2017/059435. [cited by applicant]
Abe et al. (Jul. 1, 1998), “Enhanced Gene Transfer with Fusogenic Liposomes Containing Vesicular Stomatitis Virus G Glycoprotein,” Journal of Virology, 72(7), 6159-6163. [cited by applicant]
Adlakha-Hutcheon et al. (Aug. 1999), “Controlled destabilization of a liposome drug delivery system enhances mitoxantrone antitumor activity,” Nature Biotechnology, 17, 775-779. [cited by applicant]
Agarwal et al., “In vivo generated human CAR T cells eradicate tumor cells,” OncoImmunology (2019) 8(12): e1671761, 7 pages. [cited by applicant]
Agarwal et al., “In Vivo Generation of CAR T Cells Selectively in Human CD4+ Lymphocytes,” Mol Ther. (2020) 28(8):1783-1794. [cited by applicant]
Agrawal et al., “Complement Evasion Strategies of Viruses: An Overview,” Front Microbiol. (2017) Jun. 16; 8:1117. [cited by applicant]
Ali et al., “ Virosome: An engineered virus for vaccine delivery,” Saudi Pharmaceuticals Journal (2023), vol. 31, p. 752-764. [cited by applicant]
Alvarez-Erviti et al., “Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes.” Nature Biotechnology (2011) 29(4): 341-345. [cited by applicant]
Bagai et al., “ Targeted Delivery of Hygromycin B Using Reconstituted Sendai Viral Envelopes Lacking Hemagglutinin-neuraminidase,” FEBS (1993), vol. 277, p. 183-188. [cited by applicant]
Bakshi et al., “Engineering Single Domain Antibodies Into Antivirals and Vaccine Delivery Vehicles to Combat Infectious Diseases,” Diss. Ghent University (2019). [cited by applicant]
Bannas et al. (Nov. 22, 2017), “Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics,” Frontiers in Immunology, 8(1603), in 13 pages. [cited by applicant]
Blechacz et al. (Jun. 2008), “Measles Virus as An Oncolytic Vector Platform,” Current Gene Therapy, 8(3), 162-175. [cited by applicant]
Brown et al., “A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice,” Blood. (2007) 110(13): 4144-4152. [cited by applicant]
Carter et al., “Versatile in vivo genome editing with the prototypical Streptococcus thermophilus CRISPR1-Cas9 system,” BioRxiv. (2018); 10 pages. [cited by applicant]
Cattaneo, “Paramyxovirus entry and targeted vectors for cancer therapy,” PLoS Pathog. (2010) 6(6): e1000973. [cited by applicant]
Challener, “Advances in In Vivo CAR T-cell Therapies,” BioPharm International (Mar. 7, 2023) 2(3):4 pages. [cited by applicant]
Chen et al., “Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma,” Cancer Immunol. Immunother.… [cited by applicant]
Costello et al., “Gene transfer into stimulated and unstimulated T lymphocytes by HIV-1-derived lentiviral vectors” Gene Ther. (2000) 7(7):596-604. [cited by applicant]
David et al., “Viral Vectors: The Road to Reducing Genotoxicity,” Toxicol Sci. (2017) 155(2):315-325. [cited by applicant]
Eisenstein et al. (2020), “Nature Biotechnology's academic spinouts of 2019,” Nature Biotechnology (2020) 38:546-547. [cited by applicant]
Escors et al., “Cell and Tissue Gene Targeting with Lentiviral Vectors,” Lentiviral Vectors and Gene Therapy. (2012) 29-50. [cited by applicant]
Ezigbo et al. (Sep. 30, 2014), “Hepatocellular carcinoma in a patient with chronic lymphocytic leukaemia involving the liver,” BMJ Case Report, 1-3. [cited by applicant]
Felt et al., “Recent Advances in Vesicular Stomatitis Virus-Based Oncolytuc Virotherapy: a 5-year Update,” Journal of General Virology (2017), vol. 98, p. 2895-2911. [cited by applicant]
Field et al. (Jan. 12, 2017), “Interleukin-2 receptor-a proximal promoter hypothylation is associated with multiple sclerosis,” Genes and Immunity, 18, 59-66. [cited by applicant]
Frank et al., “Surface-Engineered Lentiviral Vectors for Selective Gene Transfer into Subtypes of Lymphocytes,” Mol Ther Methods Clin Dev. (2019) 12:19-31. [cited by applicant]
Funke et al., “Targeted cell entry of lentiviral vectors,” Mol. Ther. (2008) 16(8):1427-1436. [cited by applicant]
Galimi et al., “Development of Ecdysone-Regulated Lentiviral Vectors,” Molecular Therapy (2005) 11(1):142-148. [cited by applicant]
Ghassemi et al., “Rapid manufacturing of non-activated potent CAR T cells,” Nat Biomed Eng. (2022) 6(2):118-128. [cited by applicant]
Girard-Gagnepain (Nov. 11, 2014), “Evaluation of new lentiviral vector pseudotypes for gene transfer into hematopoietic cells,” Virology, Ecole normale supérieure de lyon-ENSLYON, NNT: 2014ENSL0939. tel-01084864, in 393… [cited by applicant]
Girard-Gagnepain et al., “Baboon envelope pseudotyped LVs outperform VSV-G-LVs for gene transfer into early-cytokine-stimulated and resting HSCs,” Blood (2014) 124(8):1221-1231. [cited by applicant]
Gonzales-Aseguinolaza et al. (Sep. 2010), “Durable Correction of Inherited Metabolic Liver Disorders Requires Preventing Transgene Off-Targeting From Gene Therapy Vectors: The Value of MicroRNAs,” Gastroenterology, 139(… [cited by applicant]
Gorelik et al. (Jan. 2002), “Transforming Growth Factor-B in T-Cell Biology,” Nature Reviews Immunology, 2, 46-53. [cited by applicant]
Gori et al., “Protection of mice from methotrexate toxicity by ex vivo transduction using lentivirus vectors expressing drug-resistant dihydrofolate reductase,” J Pharmacol Exp Ther (2007) 322(3):989-97. [cited by applicant]
Greenberg et al., “Targeted transgene expression in muller glia of normal and diseased retinas using lentiviral vectors,” IOVS (2007) 48(4):1844-1852. [cited by applicant]
Hafid et al., “Phenylketonuria: a review of current and future treatments,” Transl Pediatr. (2015) (4):304-17. [cited by applicant]
Hassett et al. (Apr. 15, 2019), “Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccine,” Molecular Therapy-Nucleic Acids, in 11 pages. [cited by applicant]
International PCT Application PCT/US2025/017875, filed Feb. 28, 2025, by Sana Biotechnology, Inc., in 487 pages. [cited by applicant]
Joglekar et al. (Dec. 1, 2017), “Pseudotyped Lentiviral Vectors: One Vectors, Many Guises,” Human Gene Therapy Methods, 2017, 28(6), 11 pages. [cited by applicant]
Juzenas et al., “A comprehensive, cell specific microRNA catalogue of human peripheral blood,” Nucleic Acids Research (2017), vol. 45 (16), p. 9290-9301. [cited by applicant]
Kanvinde et al., “Non-Viral Vectors for Delivery of Nucleic Acid Therapies for Cancer,” BioTech (Basel) (2022) 11(1):6, 4 pages. [cited by applicant]
Kasaraneni et al. (Dec. 12, 2017), “Retargeting Lentiviruses via SpyCatcher-SpyTag Chemistry for Gene Delivery into Specific Cell Types,” mBio, 8(6), in 12 pages. [cited by applicant]
Kaur et al. (2014), “CD47 Signaling Regulates the Immunosuppressive Activity of VEGF in T Cells,” The Journal of Immunology, 193(8), 3914-3924. [cited by applicant]
Kells et al., “Efficient gene therapy-based method for the delivery of therapeutics to primate cortex”. PNAS (106):2407-2411, 2009. [cited by applicant]
Kneissl et al., “Measles Virus Glycoprotein-Based Lentiviral Targeting Vectors That Avoid Neutralizing Antibodies,” PLOS One (2012) 7(10): e46667. [cited by applicant]
Lam et al., “Efficient and Safe Herpes Simplex Virus Type 1 Amplicon Vector for Transpictionally Targeted Therapy for Human Hepatocellular Carcinomas,” The American Society of Gene Therapy (2007), vol. 15, No. 6, p. 112… [cited by applicant]
Levy et al. (Oct. 24, 2017), “Measles virus envelope pseudotyped lentiviral vectors transduce quiescent human HSCs at an efficiency without precedent,” Blood Advances, 1(23), in 17 pages. [cited by applicant]
Li, “Enhancing HSP70-ShRNA Transfection in 22RV1 Prostate Cancer Cells by Combination of Sonoporation, Liposomes and HTERTA-CMV Chimeric Promoter,” International Journal of Oncology (2013), vol. 43, p. 151-158. [cited by applicant]
Mhaidly et al. (Apr. 1, 2019), “The Future: In Vivo CAR T Cell Gene Therapy”, Molecular Therapy, 2019, 27(4), 3 pages. [cited by applicant]
Miao et al., “Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro,” Mol Ther. (2000) 1(6):522-32. [cited by applicant]
Milani et al., “Phagocytosis-shielded lentiviral vectors improve liver gene therapy in nonhuman primates,” Sci Transl Med. (2019) 11(493): eaav7325. [cited by applicant]
Moll et al., “Importance of the cytoplasmic tails of the measles virus glycoproteins for fusogenic activity and the generation of recombinant measles viruses,” J Virol. (2002) 76(14): 7174-86. [cited by applicant]
Nakamura et al., “Oncolytic Measles Viruses for Cancer Therapy,” Expert Opinion on Biological Therapy (2004), vol. 4, No. 10, p. 1685-1692. [cited by applicant]
Nomura et al. (Feb. 26, 2004), “Microscopic observations reveal that fusogenic peptides induce liposome shrinkage prior to membrane fusion,” PNAS 101(10), 3420-3425. [cited by applicant]
Organism—Wikipedia p. 1 of 10 downloaded Nov. 6, 2017 Cited as: Organism—Wikipedia. Retrieved on Sep. 14, 2023. 7 pages. [cited by applicant]
Pager et al., “A mature and fusogenic form of the Nipah virus fusion protein requires proteolytic processing by cathepsin L,” Virology. (2006) 346(2): 251-257. [cited by applicant]
Pfeiffer et al., “In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome,” EMBO Mol Med. (2018) 10(11):e9158. [cited by applicant]
Plemper et al., “Structural and mechanistic studies of measles virus illuminate paramyxovirus entry,” PLoS Pathog. (2011) 7(6): e1002058. [cited by applicant]
Rockx et al. (Aug. 2012), “Recent progress in henipavirus research: molecular biology, genetic diversity, animal models,” Antiviral Research, 95(2), 135-149. [cited by applicant]
Schneider et al., “A Tandem CD19/CD20 Lentiviral Vector Drives On-Target and Off-Target Antigen Modulation in Leukemia Cell Lines,” Journal of Immunotherapy (2017), vol. 98, p. 2895-2911. [cited by applicant]
Sequences cited by the USPTO in the Office Action dated Mar. 7, 2024, in U.S. Appl. No. 17/572,611: SEQ ID No. 17 of U.S. Appl. No. 17/572,611 vs EP3235908 SEQ ID No. 4 (Year: 2017) SEQ ID No. 17 of U.S. Appl. No. 17/57… [cited by applicant]
Shim et al., “Efficient and Targeted Delivery of siRNA in Vivo,” FEBS (2010), vol. 277, p. 4814-4827. [cited by applicant]
Smith et al., “Viral entry mechanisms: the increasing diversity of paramyxovirus entry,” FEBS J. (2009) 276(24): 7217-27. [cited by applicant]
Sun, W., “Henipavirus Assembly And Budding,” Doctoral Dissertation (online). Pennsylvania 4-6, 7/4-6, 8/4-6 State University. 2015 [retrieved on Sep. 30, 2021]. Retrieved from the Internet: [URL: https://etda.libraries.… [cited by applicant]
Suvanasuthi et al., “Rapid transport of plasmid DNA into the nucleolus via actin depolymerization using the HVJ envelope vector,” J Gene Med. (2007) 9(1):55-62. [cited by applicant]
Vairy et al., “CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia,” Drug Des Devel Ther. (2018) 12:3885-3898. [cited by applicant]
Valastyan et al. (2010), “miR-31: A crucial overseer of tumor metastasis and other emerging roles,” Cell Cycle, 9(11), 2124-2129. [cited by applicant]
Verhoeyen et al. (2008), “Production of Lentiviruses Displaying “Early-Acting” Cytokines for Selective Gene Transfer into Hematopoietic Stem Cells,” Gene Therapy Protocols, 434(2), 99-112. [cited by applicant]
Wang et al., “AAV Gene Therapy Corrects OTC Deficiency and Prevents Liver Fibrosis in Aged OTC-Knock Out Heterozygous Mice,” Molecular Genetics and Metabolism (Apr. 2017), vol. 120, p. 299-305. [cited by applicant]
Wu et al., “Combinatorial control of suicide gene expression by tissue-specific promoter and microRNA regulation for cancer therapy,” Mol Ther. (2009) Dec.;17(12):2058-66. [cited by applicant]
Zhang et al. (Dec. 9, 2021), “A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques,” Nature Medicine, 27(12), in 31 pages. [cited by applicant]
Diederich et al., “Activation of the Nipah Virus Fusion Protein in MDCK Cells Is Mediated by Cathepsin B within the Endosome-Recycling Compartment,” Journal of Virology (2012) 86(7):3736-3745. [cited by applicant]
Follenzi et al. (2002), “Efficient Gene Delivery and Targeted Expression to Hepatocytes In Vivo by Improved Lentiviral Vectors,” Human Gene Therapy, 13(2), 243-260. [cited by applicant]
Transfiguracion et al. (Sep. 18, 2020), “Rapid In-Process Monitoring of Lentiviral Vector Particles by High-Performance Liquid Chromatography.,” Molecular Therapy: Methods & Clinicial Development, 18, 803-810. [cited by applicant]